FDA Grants Priority Review for Insmed's SomatoKine

The FDA has granted priority-review status to Insmed's new drug application for SomatoKine, a drug candidate intended to treat growth hormone insensitivity syndrome.

The agency established a user-fee goal date of July 3 for the application. The FDA previously granted SomatoKine (mecasermin rinfabate) orphan-drug designation.